Ixazomib

Proteasome inhibitors: key drugs in multiple myeloma

Maria-Victoria Mateos

Myeloma QoL through induction and maintenance

Key amyloidosis data from ASH 2019

Daratumumab with IRd in NDMM displays excellent activity

Maintenance therapy in MM: perspectives

Ixazomib or lenalidomide post-ASCT in NDMM

Phase 2 NFKB2 rearrangement-driven MM trial: predictor of sensitivity to PIs?

Prevention of progression: ixazomib/len/dex in high-risk SMM

Outcomes in RRMM treated with IRd in the real world

Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?

Leon Bernal-Mizrachi

How will novel agents affect the amyloidosis population?

Morie Gertz et al.

Lenalidomide and Ixazomib: a successful amyloidosis treatment combination?

Oliver Charles Cohen

Palliative treatment of waldenström’s macroglobulinemia

Prevention and management of adverse events in relapsed myeloma

Michel Delforge

Updates in amyloidosis: ISA 2020

Consolidation therapy options for myeloma post-transplant

Philip McCarthy

1
2
3
4
Next